Results 261 to 270 of about 124,093 (287)
Some of the next articles are maybe not open access.
Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation
International Journal of Andrology, 2006SummaryTo date, there is no FDA‐approved therapy for premature ejaculation (PE). Recently, phosphodiesterase 5 inhibitors (PDE5‐Is) have been demonstrated to have encouraging results in the treatment of PE by a few studies. The aim of this review was to assess the updated manuscripts and thereafter present the practical recommendations and possible ...
W F, Wang, S, Minhas, D J, Ralph
openaire +2 more sources
Phosphodiesterase 5 inhibitors in male sexual dysfunction
Current Opinion in Urology, 2003Phosphodiesterase 5 inhibitors are preferred by most men for the oral treatment of erectile dysfunction. In many guidelines, this therapy is recommended as first-line therapy because of convenience, high efficacy, and low rates of side-effects. Sildenafil was the first drug for the treatment of erectile dysfunction, introduced in 1998.
openaire +3 more sources
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia
Current Opinion in Urology, 2010Benign prostatic hyperplasia (BPH) is prevalent in old men and often results in lower urinary tract symptoms (LUTS). Phosphodiesterase-5 (PDE5) inhibitors increase intracellular concentrations of cyclic guanosine monophosphate. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.) are first-line treatments for erectile dysfunction.
openaire +2 more sources
Phosphodiesterase‐5 Inhibitors and Migraine
Headache: The Journal of Head and Face Pain, 2004Evans, Randolph W +1 more
openaire +3 more sources
Hemodynamic and Exercise Effects of Phosphodiesterase 5 Inhibitors
The American Journal of Cardiology, 2005Phosphodiesterase 5 (PDE5) inhibitors have modest nitrate-like hemodynamic effects, lowering wedge pressure, pulmonary artery pressure, and systolic and diastolic arterial pressure. At rest, decreases in arterial pressure averaging 9/8 mm Hg may increase to 12/5 mm Hg as a result of the vasodilatory response, but no clinical adverse effects have been ...
openaire +2 more sources
Pharmacology of phosphodiesterase 5 inhibitors.
The Canadian journal of urology, 2003The phosphodiesterase enzymes, of at least 11 types, are ubiquitous throughout the body, and perform a variety of functions. Phosphodiesterase type 5 (PDE5) is the predominant enzyme in the corpus cavernosum, and plays a crucial role in penile erection.
openaire +1 more source
Phosphodiesterase 5 inhibitors and adrenal incidentalomas
Medical Hypotheses, 2019Ioannis, Ilias, Lina, Zabuliene
openaire +2 more sources
Phase 4 Studies on Phosphodiesterase 5 Inhibitors
JAMA Ophthalmology, 2022Brian L, VanderBeek, Maureen G, Maguire
openaire +2 more sources